Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma
It is a RCT aimed to evaluate the Progression Free Survival of Camrelizumab combined with apatinib and temozolomide as First Line Therapy in Advanced Acral Melanoma.
Acral Melanoma
DRUG: camrelizumab+apatinib+TMZ|DRUG: camrelizumab+apatinib|DRUG: camrelizumab
Progression Free Survival, PFS, PFS was defined as the time from randomization to progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or death due to any cause, whichever occurs first., Within 2 years
Overall Survival ,OS, OS will be defined as the time from randomization to death due to any cause., Within 2 years|ORR, The objective response rate will be assessed by RECIST 1.1, Within 2 years|DCR, The disease control rate will be assessed by RECIST 1.1, Within 2 years|Adverse Events (AEs), An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily had to have a causal relationship with this treatment., Within 2 years
It is a RCT aimed to evaluate the Progression Free Survival of Camrelizumab combined with apatinib and temozolomide as First Line Therapy in Advanced Acral Melanoma.